Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Ganglioglioma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	cobimetinib Sensitive: A2 - Guideline cobimetinib Sensitive : A2	cobimetinib Sensitive: A2 - Guideline cobimetinib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
BRAF V600	Ganglioglioma	BRAF V600	Ganglioglioma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
BRAF V600	Ganglioglioma	BRAF V600	Ganglioglioma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
BRAF V600	Ganglioglioma	BRAF V600	Ganglioglioma	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1
BRAF V600	Ganglioglioma	BRAF V600	Ganglioglioma	MEK inhibitor + BRAF inhibitor Sensitive: C3 – Early Trials MEK inhibitor + BRAF inhibitor Sensitive : C3	MEK inhibitor + BRAF inhibitor Sensitive: C3 – Early Trials MEK inhibitor + BRAF inhibitor Sensitive : C3
BRAF T599	Ganglioglioma	BRAF T599	Ganglioglioma	trametinib + dabrafenib Sensitive: C4 – Case Studies trametinib + dabrafenib Sensitive : C4	trametinib + dabrafenib Sensitive: C4 – Case Studies trametinib + dabrafenib Sensitive : C4